ELSEVIER

International Journal of Antimicrobial Agents 16 (2000) 559–563

INTERNATIONAL JOURNAL OF
Antimicrobial Agents

www.ischemo.org

Author index

Volume 16 (2000)

Ackermann, G., see Schaumann, R. **16**, 225
Agostoni, F., C. Atzori, E. Angeli, A. Mainini, V. Micheli and A. Cargnel, *Pneumocystis carinii* diagnosis: an update **16**, 549
Akaki, T., see Sato, K. **16**, 25
Allen, A., E. Bygate, D. Clark, A. Lewis and V. Pay, The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers **16**, 45
Allerberger, F., see Bujdáková, H. **16**, 31
Amalfitano, M.E., see Bassetti, M. **16**, 295
Amaral, L., see Bettencourt, M.V. **16**, 69
Andriole, V.T., Current and future antifungal therapy: new targets for antifungal therapy **16**, 317
Angeli, E., see Agostoni, F. **16**, 549
Annibale, B., G. Capurso, G. Martino, C. Grossi and G. Delle Fave, Iron deficiency anaemia and *Helicobacter pylori* infection **16**, 515
Antonelli, G., see Turriziani, O. **16**, 353
Aoun, M., Standard antifungal therapy in neutropenic patients **16**, 143
Appelbaum, P.C. and P.A. Hunter, The fluoroquinolone antibacterials: past, present and future perspectives **16**, 5
Appelbaum, P.C., see Jacobs, M.R. **16**, 17
Appelbaum, P.C., see Syrogiannopoulos, G.A. **16**, 219
Arida, C., see Kouppari, G. **16**, 254
Ascione, T., see Esposito, S. **16**, 495
Ashraful Haq, J., see Zahurul Haque Asna, S.M. **16**, 249
Atzori, C., see Agostoni, F. **16**, 549

Bagová, M., see Bujdáková, H. **16**, 31
Baldanti, F., see Gerna, G. **16**, 455
Ball, P., New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost? **16**, 263
Barišic, Z. and V. Punda-Polic, Antibiotic resistance among enterococcal strains isolated from clinical specimens **16**, 65
Bartolone, M.R., see Lombardi, A. **16**, 461
Bassetti, D., see Bassetti, M. **16**, 295
Bassetti, D., see Beltrame, A. **16**, 363
Bassetti, D., see Beltrame, A. **16**, 361
Bassetti, D., see Boni, S. **16**, 371
Bassetti, D., see Fiore, P. **16**, 365
Bassetti, D., see Pontali, E. **16**, 349
Bassetti, M., A. Di Biagio, B. Rebesco, G. Cenderello, M.E. Amalfitano and D. Bassetti, Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy **16**, 295
Bassetti, M., see Beltrame, A. **16**, 361
Bassetti, M., see Pontali, E. **16**, 349
Bax, R., N. Mullan and J. Verhoef, The millennium bugs — the need for and development of new antibacterials **16**, 51
Beltrame, A., D. Gori, F. Marenco, D. Bassetti and F. Henriquet, Analysis of drug costs in a domiciliary care unit for AIDS patients: a 3-year survey **16**, 363
Beltrame, A., V. Del Bono, M. Marturano, P. Pedemonte, R. Rosso, G. Mazzarello, M. Bassetti, A. Collidà, F. Fusco and D. Bassetti, Tolerance of highly active antiretroviral therapy in HIV patients: a 3-year follow up **16**, 361
Bergeron, M.G., Genetic tools for the simultaneous identification of bacterial species and their antibiotic resistance genes: impact on clinical practice **16**, 1
Bergogne-Bérézin, E., Treatment and prevention of antibiotic associated diarrhea **16**, 521
Berkiten, R., see Gönüllü, N. **16**, 77
Bertagnolio, S., see de Gaetano Donati, K. **16**, 357
Besana, S., see Rosina, M. **16**, 435
Bettencourt, M.V., S. Bosne-David and L. Amaral, Comparative in vitro activity of phenothiazines against multidrug-resistant *Mycobacterium tuberculosis* **16**, 69
Bille, J., Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients **16**, 87
Bille, J., Mechanisms and clinical significance of antifungal resistance **16**, 331
Boccazzi, A., P. Tonelli and R. Ceruti, What's new in streptococcal pharyngitis **16**, 287
Bodey, G.P., Unusual presentations of infection in neutropenic patients **16**, 93
Bonaccorso, C., see Drago, L. **16**, 545
Böni, J., see Schüpbach, J. **16**, 441
Boni, S., E. Pontali, P. De Gol, P. Pedemonte and D. Bassetti, Compliance to combination antiretroviral therapy in HIV-1 infected children **16**, 371
Boni, S., see Fiore, P. **16**, 365
Boni, S., see Pontali, E. **16**, 349
Bonner, D., see Huczko, E. **16**, 401
Bosne-David, S., see Bettencourt, M.V. **16**, 69
Brenner, B., M.A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R.-P. Sekaly, B. Conway and J.-P. Routy, Resistance to antiretroviral drugs in patients with primary HIV-1 infection **16**, 429
Bujdáková, H., J. Klimáčková, F. Allerberger, M. Moravčíková, M. Bagová, J. Hanzen, D. Michálková-Papajová, M.P. Dierich and M. Kettner, Spectrum and transferability of β-lactam resistance in hospital strains of *Enterobacter* isolated in Bratislava and Innsbruck **16**, 31
Bygate, E., see Allen, A. **16**, 45

Callari, A., see Strippoli, V. **16**, 73
Cammà, C., see Prestileo, T. **16**, 373

PII: S0924-8579(00)00326-5

Capurso, G., see Annibale, B. **16**, 515
Cargnel, A., see Agostoni, F. **16**, 549
Cargnel, A., see Rosina, M. **16**, 435
Cassetta, M.I., see Novelli, A. **16**, 501
Castillo, J., see Gomez-Lus, R. **16**, 335
Cataldo, I., see Lequaglie, C. **16**, 541
Cataldo, M., see de Gaetano Donati, K. **16**, 357
Cauda, R., see de Gaetano Donati, K. **16**, 357
Cenderello, G., see Bassetti, M. **16**, 295
Ceruti, R., see Boccazzi, A. **16**, 287
Chodosh, S., see Meinl, B. **16**, 273
Chomarat, M., Resistance of bacteria in urinary tract infections **16**, 483
Cinelli, R., see Corti, G. **16**, 527
Clark, D., see Allen, A. **16**, 45
Claros, M.C., see Schaumann, R. **16**, 225
Clavel, A., see Gomez-Lus, R. **16**, 335
Colletti, P., see Prestileo, T. **16**, 373
Collidà, A., see Beltrame, A. **16**, 361
Colucci, G., New technologies and applications of PCR in clinical diagnosis **16**, 499
Conetta, B., see Huczko, E. **16**, 401
Conti., S., see Novelli, A. **16**, 501
Conway, B., see Brenner, B. **16**, 429
Cornaglia, G. and R. Fontana, Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy **16**, 259
Corti, G., R. Cinelli and F. Paradisi, Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic **16**, 527
Craxì, A., see Prestileo, T. **16**, 373
Crokaert, F., Febrile neutropenia in children **16**, 173
Cruciani, M., Antibacterial prophylaxis **16**, 123

Dagan, R., see Syrogiannopoulos, G.A. **16**, 219
Dascal, A., see Brenner, B. **16**, 429
D'Auria, F.D., see Strippoli, V. **16**, 73
Davies, T.A., see Syrogiannopoulos, G.A. **16**, 219
De Benedetto, F., see Sanguinetti, C.M. **16**, 467
De Bock, R. and A.Z. Middelheim, Febrile neutropenia in allogeneic transplantation **16**, 177
de Gaetano Donati, K., S. Bertagnolio, M. Tumbarello, E. Tacconelli, M. Cataldo, B. Longo and R. Cauda, Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects **16**, 357
De Gol, P., see Boni, S. **16**, 371
de Jong, J.J., see Lukashov, V.V. **16**, 463
Del Bono, V., see Beltrame, A. **16**, 361
Del Favero, A., Management of fungal infections in neutropenic patients: more doubts than certainties? **16**, 135
Delle Fave, G., see Annibale, B. **16**, 515
De Pauw, B.E., New antifungal agents and preparations **16**, 147
de Ronde, A., see Lukashov, V.V. **16**, 463
De Vecchi, E., see Drago, L. **16**, 545
De Vecchi, E., see Drago, L. **16**, 479
Dianzani, F., see Turriziani, O. **16**, 353
Di Biagio, A., see Bassetti, M. **16**, 295
Dierich, M.P., see Bujdáková, H. **16**, 31
Di Lorenzo, F., see Prestileo, T. **16**, 373
Di Stefano, R., see Prestileo, T. **16**, 373
Donelli, E., see Fiore, P. **16**, 365
Donnelly, J.P., Febrile neutropenia: antifungal prophylaxis **16**, 127
Drago, L., B. Mombelli, E. De Vecchi, C. Bonaccorso, M.C. Fassina and M.R. Gismondo, *Candida albicans* cellular internalization: a new pathogenic factor? **16**, 545
Drago, L., B. Mombelli, E. De Vecchi, L. Tocalli, G. Nardi and M.R. Gismondo, Epidemiology of Gram-negative antibiotic resistance in outpatients: a year of surveillance **16**, 479
Drago, L., see Lombardi, A. **16**, 461
Ducóns, J.A., see Ferrero, M. **16**, 245
Duque, C., see Rodríguez, A.J. **16**, 253

Esposito, S. and T. Ascione, Short-course treatment for acute tonsillopharyngitis **16**, 495

Fallani, S., see Novelli, A. **16**, 501
Fassina, M.C., see Drago, L. **16**, 545
Feld, R., Multinational cooperation in trials and guidelines dealing with febrile neutropenia **16**, 185
Ferraro, D., see Prestileo, T. **16**, 373
Ferrero, M., J.A. Ducóns, B. Sicilia, S. Santolaria, E. Sierra and F. Gomollón, Factors affecting the variation in antibiotic resistance of *Helicobacter pylori* over a 3-year period **16**, 245
Fiore, P., E. Donelli, S. Boni, E. Pontali, R. Tramalloni and D. Bassetti, Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors **16**, 365
Firsov, A.A., S.H. Zinner, I.Y. Lubenko and S.N. Vostrov, Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses **16**, 407
Flepp, M., see Schüpbach, J. **16**, 441
Fontana, R., see Cornaglia, G. **16**, 259
Forrest, A., see Meinl, B. **16**, 273
Fung-Tomc, J., see Huczko, E. **16**, 401
Furr, J.R., see Tattawasart, U. **16**, 233
Fusco, F., see Beltrame, A. **16**, 361

Gallo, R.C., New concepts for future control of HIV derived from studies of pathogenesis **16**, 421
Gál, Z., D. Szabó, P. Kovács, F. Hernádi, B. Tóth-Martinez and F. Rozgonyi, β-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing β-lactamases of gram-negative extraintestinal clinical isolates **16**, 395
García, A., see Rodríguez, A.J. **16**, 253
García-Rodríguez, J.A. and J.L. Muñoz Bellido, The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia **16**, 281
Gerna, G., F. Baldanti, J. Middeldorp and D. Lilleri, Use of CMV transcripts for monitoring of CMV infections in transplant recipients **16**, 455
Giamarellou, H., Anaerobic infection therapy **16**, 341
Giamarellou, H., Therapeutic guidelines for *Pseudomonas aeruginosa* infections **16**, 103
Ginocchio, C.C., Laboratory diagnosis of human cytomegalovirus (HCMV) central nervous system disease in AIDS patients **16**, 447
Girmenia, C., see Martino, P. **16**, 323
Girmenia, C., see Martino, P. **16**, 303
Gismondo, M.R., see Drago, L. **16**, 545
Gismondo, M.R., see Drago, L. **16**, 479
Gismondo, M.R., see Lombardi, A. **16**, 461
Gismondo, M.R., see Mombelli, B. **16**, 531
Gismondo, M.R., see Rosina, M. **16**, 435
Giudice, G., see Lequaglie, C. **16**, 541
Goldstein, E.J.C., see Schaumann, R. **16**, 225
Gomez-Lus, R., A. Clavel, J. Castillo, C. Seral and C. Rubio, Emerging and reemerging pathogens **16**, 335
Gomollón, F., see Ferrero, M. **16**, 245
Gönüllü, N. and R. Berkiten, Antimicrobial resistance of clinical isolates of *Streptococcus pneumoniae* in Istanbul **16**, 77
Gori, D., see Beltrame, A. **16**, 363
Goudsmit, J., see Lukashov, V.V. **16**, 463
Gould, J.C., see Krupova, Y. **16**, 79
Graf, B.M. and E. Martin, The intensive care physician and control of antimicrobial resistance **16**, 511

Grivea, I., see Syrogiannopoulos, G.A. **16**, 219
Groll, A., see Walsh, T.J. **16**, 151
Grossi, C., see Annibale, B. **16**, 515

Hammerschlag, M.R., see Roblin, P.M. **16**, 61
Hanzen, J., see Bujdáková, H. **16**, 31
Henriquet, F., see Beltrame, A. **16**, 363
Hernádi, F., see Gál, Z. **16**, 395
Herrstedt, J., Prevention and management of mucositis in patients with cancer **16**, 161
Hollauer, K., see Naber, K.G. **16**, 239
Huczko, E., B. Conetta, D. Bonner, L. Valera, T. Stickle, A. Macko and J. Fung-Tomc, Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997–1998 **16**, 401
Hunter, P.A., see Appelbaum, P.C. **16**, 5
Hyatt, J.M., see Meinl, B. **16**, 273

Jacobs, M.R. and P.C. Appelbaum, Susceptibility of 1100 *Streptococcus pneumoniae* strains isolated in 1997 from seven Latin American and Caribbean countries **16**, 17
Jacobs, M.R., see Syrogiannopoulos, G.A. **16**, 219
Jeljaszewicz, J., G. Mlynarczyk and A. Mlynarczyk, Antibiotic resistance in Gram-positive cocci **16**, 473

Kawahara, S., see Sato, K. **16**, 25
Kern, W.V., Modifications of therapy **16**, 139
Kettner, M., see Bujdáková, H. **16**, 31
Kirchbauer, D., see Naber, K.G. **16**, 239
Klastersky, J., **16**, 83
Klastersky, J., Empirical treatment of sepsis in neutropenic patients **16**, 131
Klimáčková, J., see Bujdáková, H. **16**, 31
Kõljalg, S., see Naaber, P. **16**, 309
Kouppari, G., H. Papadaki, C. Arida, J. Sakellariou, N.J. Legakis and J. Papaparaskevas, First report of ampicillin and glycopeptide resistant *Enterococcus faecium* VanA bacteraemia in Greece **16**, 254
Kovács, P., see Gál, Z. **16**, 395
Krcmery, V., Jr, Is there in vivo–in vitro correlation between antifungal susceptibility, species of *Candida* spp. and clinical outcome? **16**, 537
Krupova, Y. and J.C. Gould, The relationship between resistance in bacteria and antibiotic use in neurology and haematology units **16**, 79

Lakatos, M., see Rodríguez, A.J. **16**, 253
Ledergerber, B., see Schüpbach, J. **16**, 441
Lee, J.K., D. Peters, A.A. Obias, G.A. Noskin and L.R. Peterson, Activity of voriconazole against *Candida albicans* and *Candida krusei* isolated since 1984 **16**, 205
Legakis, N.J., see Kouppari, G. **16**, 254
Lequaglie, C., G. Giudice, P.P.B. Massone and I. Cataldo, Antifungal therapy in thoracic cancer patients with low dose liposomal amphotericin B (AmBisome) **16**, 541
Lewis, A., see Allen, A. **16**, 45
Liberti, A. and L. Loiacono, Ciprofloxacin versus chloramphenicol in the treatment of salmonella infection **16**, 347
Lilleri, D., see Gerna, G. **16**, 455
Loiacono, L., see Liberti, A. **16**, 347
Lombardi, A., L. Drago, M.R. Bartolone and M.R. Gismondo, Cytomegalovirus pp65 antigenemia in HIV patients: retrospective on 3 years study **16**, 461
Longo, B., see de Gaetano Donati, K. **16**, 357
Lubenko, I.Y., see Firsov, A.A. **16**, 407
Lukashov, V.V., A. de Ronde, J.J. de Jong and J. Goudsmit, Epidemiology of HIV-1 and emerging problems **16**, 463

Macko, A., see Huczko, E. **16**, 401
Maillard, J.-Y., see Tattawasart, U. **16**, 233
Maimets, M., see Naaber, P. **16**, 309
Mainini, A., see Agostoni, F. **16**, 549
Marenco, F., see Beltrame, A. **16**, 363
Martin, E., see Graf, B.M. **16**, 511
Martino, G., see Annibale, B. **16**, 515
Martino, P. and C. Girmenia, Making the diagnosis of fungal infection: when to start treatment **16**, 323
Martino, P. and C. Girmenia, The role of antimicrobial policies in neutropenic patients **16**, 303
Marturano, M., see Beltrame, A. **16**, 361
Massone, P.P.B., see Lequaglie, C. **16**, 541
Mazzarello, G., see Beltrame, A. **16**, 361
Mazzola, G., see Prestileo, T. **16**, 373
McNabb, J.C., R.C. Owens, D. Xuan, R. Quintiliani, C.H. Nightingale and D.P. Nicolau, Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS **16**, 37
Mégraud, F., Strategies to treat patients with antibiotic resistant *Helicobacter pylori* **16**, 507
Meijomil, P., see Rodríguez, A.J. **16**, 253
Meinl, B., J.M. Hyatt, A. Forrest, S. Chodosh and J.J. Schentag, Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone **16**, 273
Michálková-Papajová, D., see Bujdáková, H. **16**, 31
Micheli, V., see Agostoni, F. **16**, 549
Micheli, V., see Rosina, M. **16**, 435
Middeldorp, J., see Gerna, G. **16**, 455
Middelheim, A.Z., see De Bock, R. **16**, 177
Milkovich, G., The role of the hospital pharmacist in cost control and antibiotic policy **16**, 291
Miragliotta, G., see Sanguinetti, C.M. **16**, 467
Mlynarczyk, A., see Jeljaszewicz, J. **16**, 473
Mlynarczyk, G., see Jeljaszewicz, J. **16**, 473
Molina, N., see Rodríguez, A.J. **16**, 253
Mombelli, B. and M.R. Gismondo, The use of probiotics in medical practice **16**, 531
Mombelli, B., see Drago, L. **16**, 545
Mombelli, B., see Drago, L. **16**, 479
Moravčíková, M., see Bujdáková, H. **16**, 31
Moroni, M., see Rusconi, S. **16**, 425
Mullan, N., see Bax, R. **16**, 51
Muñoz Bellido, J.L., see García-Rodríguez, J.A. **16**, 281

Naaber, P., S. Kõljalg and M. Maimets, Antibiotic usage and resistance — trends in Estonian University Hospitals **16**, 309
Naber, K.G., K. Hollauer, D. Kirchbauer and W. Witte, In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections **16**, 239
Nadal, D., see Schüpbach, J. **16**, 441
Nardi, G., see Drago, L. **16**, 479
Nicolau, D.P., see McNabb, J.C. **16**, 37
Nightingale, C.H., see McNabb, J.C. **16**, 37
Ninane, V., Radiological and invasive diagnosis in the detection of pneumonia in febrile neutropenia **16**, 91
Nord, C.E., see van der Waaij, D. **16**, 191
Noskin, G.A., see Lee, J.K. **16**, 205
Novelli, A., S. Fallani, M.I. Cassetta and S. Conti., Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics **16**, 501

Obias, A.A., see Lee, J.K. **16**, 205
Opravil, M., see Schüpbach, J. **16**, 441
Owens, R.C., see McNabb, J.C. **16**, 37

Paesmans, M., Risk factors assessment in febrile neutropenia **16**, 107
Pal, A. and A.K. Pal, Studies on the genotoxicity of turmeric extracts in bacterial system **16**, 415
Pal, A.K., see Pal, A. **16**, 415
Papadaki, H., see Kouppari, G. **16**, 254
Papaparaskevas, J., see Kouppari, G. **16**, 254
Paradisi, F., see Corti, G. **16**, 527
Pay, V., see Allen, A. **16**, 45
Pedemonte, P., see Beltrame, A. **16**, 361
Pedemonte, P., see Boni, S. **16**, 371
Pedemonte, P., see Pontali, E. **16**, 349
Peters, D., see Lee, J.K. **16**, 205
Peterson, L.R., see Lee, J.K. **16**, 205
Pless, B., see Schaumann, R. **16**, 225
Pontali, E., P. Pedemonte, M. Bassetti, S. Boni and D. Bassetti, Does HGV–HIV co-infection exist? **16**, 349
Pontali, E., see Boni, S. **16**, 371
Pontali, E., see Fiore, P. **16**, 365
Porat, N., see Syrogiannopoulos, G.A. **16**, 219
Powell, M., Licensing new antibacterial agents — a European perspective **16**, 199
Prestileo, T., G. Mazzola, F. Di Lorenzo, P. Colletti, F. Vitale, D. Ferraro, R. Di Stefano, C. Cammà and A. Craxì, Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients **16**, 373
Punda-Polic, V., see Barišic, Z. **16**, 65

Quintiliani, R., see McNabb, J.C. **16**, 37

Rebesco, B., see Bassetti, M. **16**, 295
Roblin, P.M. and M.R. Hammerschlag, In vitro activity of GAR-936 against *Chlamydia pneumoniae* and *Chlamydia trachomatis* **16**, 61
Roden, M., see Walsh, T.J. **16**, 151
Rodloff, A.C., see Schaumann, R. **16**, 225
Rodríguez, A.J., C.N. Rodríguez, P. Meijomil, A. García, C. Duque, N. Molina and M. Lakatos, A 10 year study of resistance of *Staphylococcus aureus* to selected antimicrobials in three Venezuelan centres **16**, 253
Rodríguez, C.N., see Rodríguez, A.J. **16**, 253
Roilides, E., see Walsh, T.J. **16**, 151
Rolston, K.V.I., Prediction of neutropenia **16**, 113
Ronchetti, F., see Syrogiannopoulos, G.A. **16**, 219
Ronchetti, M.P., see Syrogiannopoulos, G.A. **16**, 219
Ronchetti, R., see Syrogiannopoulos, G.A. **16**, 219
Rosina, M., V. Micheli, S. Besana, C. Toia, M.R. Gismondo and A. Cargnel, Genotyping in HIV drug resistance mutations: epidemiology in 145 patients **16**, 435
Rosso, R., see Beltrame, A. **16**, 361
Rouleau, D., see Brenner, B. **16**, 429
Routy, J.-P., see Brenner, B. **16**, 429
Rozgonyi, F., see Gál, Z. **16**, 395
Rubenstein, E.B., Colony stimulating factors in patients with fever and neutropenia **16**, 117
Rubio, C., see Gomez-Lus, R. **16**, 335
Rusconi, S. and M. Moroni, Clinical impact of anti retroviral resistance testing: current problems and future directions **16**, 425
Russell, A.D., see Tattawasart, U. **16**, 233

Sakellariou, J., see Kouppari, G. **16**, 254
Salomon, H., see Brenner, B. **16**, 429
Sanguinetti, C.M., F. De Benedetto and G. Miragliotta, Bacterial agents of lower respiratory tract infections (LRTIs), β-lactamase production, and resistance to antibiotics in elderly people **16**, 467
Santolaria, S., see Ferrero, M. **16**, 245
Sato, K., H. Tomioka, T. Akaki and S. Kawahara, Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against *Mycobacterium tuberculosis* and *Mycobacterium avium* complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines **16**, 25
Schaumann, R., G. Ackermann, B. Pless, M.C. Claros, E.J.C. Goldstein and A.C. Rodloff, In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria **16**, 225
Schentag, J.J., see Meinl, B. **16**, 273
Schüpbach, J., Z. Tomasik, D. Nadal, B. Ledergerber, M. Flepp, M. Opravil and J. Böni, Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure **16**, 441
Sefton, A.M., The impact of resistance on the management of urinary tract infections **16**, 489
Sekaly, R.-P., see Brenner, B. **16**, 429
Seral, C., see Gomez-Lus, R. **16**, 335
Shah, P.M., Sequential or switch treatment — which criteria should be fulfilled? **16**, 301
Sicilia, B., see Ferrero, M. **16**, 245
Sierra, E., see Ferrero, M. **16**, 245
Simonetti, G., see Strippoli, V. **16**, 73
Snoeck, R., Antiviral therapy of herpes simplex **16**, 157
Spira, B., see Brenner, B. **16**, 429
Stefani, S., Changes in the resistance patterns among upper respiratory tract infection pathogens **16**, 493
Stickle, T., see Huczko, E. **16**, 401
Stock, I. and B. Wiedemann, Natural antibiotic susceptibility of *Salmonella enterica* strains **16**, 211
Strippoli, V., F.D. D'Auria, M. Tecca, A. Callari and G. Simonetti, Propyl gallate increases in vitro antifungal imidazole activity against *Candida albicans* **16**, 73
Syrogiannopoulos, G.A., F. Ronchetti, R. Dagan, I. Grivea, M.P. Ronchetti, N. Porat, T.A. Davies, R. Ronchetti, P.C. Appelbaum and M.R. Jacobs, Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B *Streptococcus pneumoniae* in Greece, Italy and Israel **16**, 219
Szabó, D., see Gál, Z. **16**, 395
Szucs, T.D., Medical economic considerations of supportive cancer care **16**, 181

Tacconelli, E., see de Gaetano Donati, K. **16**, 357
Talcott, J.A., Out-patient management of febrile neutropenia **16**, 169
Tattawasart, U., J.-Y. Maillard, J.R. Furr and A.D. Russell, Outer membrane changes in *Pseudomonas stutzeri* resistant to chlorhexidine diacetate and cetylpyridinium chloride **16**, 233
Tattersall, M.H.N., Febrile neutropenia: a necessary evil? **16**, 85
Tecca, M., see Strippoli, V. **16**, 73
Tocalli, L., see Drago, L. **16**, 479
Toia, C., see Rosina, M. **16**, 435
Tomasik, Z., see Schüpbach, J. **16**, 441
Tomioka, H., see Sato, K. **16**, 25
Tonelli, P., see Boccazzi, A. **16**, 287
Tóth-Martinez, B., see Gál, Z. **16**, 395
Tramalloni, R., see Fiore, P. **16**, 365
Tumbarello, M., see de Gaetano Donati, K. **16**, 357
Turriziani, O., G. Antonelli and F. Dianzani, Cellular factors involved in the induction of resistance of HIV to antiretroviral agents **16**, 353

Valera, L., see Huczko, E. **16**, 401
van der Waaij, D. and C.E. Nord, Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem **16**, 191
Verhoef, J., see Bax, R. **16**, 51
Viot, M., Intravenous access: related problems in oncology **16**, 165
Vitale, F., see Prestileo, T. **16**, 373
Vostrov, S.N., see Firsov, A.A. **16**, 407

Wainberg, M.A., see Brenner, B. **16**, 429
Wainwright, M., Methylene blue derivatives — suitable photoantimicrobials for blood product disinfection? **16**, 381
Walsh, T.J., M. Roden, E. Roilides and A. Groll, Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients **16**, 151
Wiedemann, B., see Stock, I. **16**, 211
Witte, W., see Naber, K.G. **16**, 239
Xuan, D., see McNabb, J.C. **16**, 37

Zahurul Haque Asna, S.M. and J. Ashraful Haq, Decrease of antibiotic resistance in *Salmonella typhi* isolated from patients attending hospitals of Dhaka City over a 3 year period **16**, 249
Zinner, S.H., New pathogens in neutropenic patients with cancer: an update for the new millennium **16**, 97
Zinner, S.H., see Firsov, A.A. **16**, 407